After Hours Summary: DARA +25.5%, CTRP +10.9%, SHAK +9.6%, MBLX -30.8%, DGLY -18%, ANY -11.3% following earnings/guidance
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings: DARA +25.5%, CADC +19.3%, CTRP +10.9%, PGN +10.3%, SHAK +9.6%, VIPS +6.9%, AXU +6.7%, NTES +4.6%, MXPT +4%, EYES +3.6%, TGB +3.6%, RNDY +2.6%, MSLI +1.7%, TCON +1.1%, MORE +0.6%, WX +0.2%
Companies trading higher in after hours in reaction to news: ONTY +14.9% (Two abstracts related to ONT-380 for the treatment of breast cancer published), VBLT +12.8% (to present positive Phase 1/2 data for VB-111 in recurrent platinum-resistant Mullerian cancer at ASCO), WLT +9.6% (disclosed that on May 7, 2015, Brian M. Chopin, Assistant Corporate Controller was appointed Acting Corporate Controller and Chief Accounting Officer, effective May 20, 2015), ISSI +6.3% (Cypress Semiconductor (CY) sent letter to the Board of Integrated Silicon Solution offering to acquire 100% of its outstanding shares of common stock for $19.75 per share in cash), NOG +4.3% (priced its private offering of $200 mln in 8% senior notes due 2020 at 95% of par), TGTX +3.6% (announced clinical data presentations at ASCO; shares up ~3.6% in after hours trade), CLSN +3.2% (announced results from its Phase Ib trial for GEN-1 in platinum-resistant ovarian cancer will be presented at the ASCO annual meeting; findings demonstrated an overall clinical benefit of 57% for all treatment arms), SAM +2.1% (increased limit for stock repurchase program by additional $50 mln, bringing total limit to $400 million), SGMO +1.3% (announced it will consolidate development plans for its zinc finger nuclease-mediated genome editing programs)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: MBLX -30.8%, DGLY -18%, ANY -11.3%, INVE -10.3%, VOXX -8.1%, HIIQ -8%, LXFT -4%, JCP -1.3%, CSCO -0.4%, JACK -0.2%, SIEN -0.1%, RVNC -0.1%
Companies trading lower in after hours in reaction to news: PBYI -21.2% (co announced publication of four abstracts for presentation at ASCO; treatment effect of PB272 (neratinib) was smaller than expected), ANY -11.3% (signed definitive agreements for a private placement of 1,281,250 Common Shares and Warrants to purchase up to 1,281,250 Common Shares for a gross purchase price of ~$4.1 mln), GEVO -10.7% (announced an offering of common stock units, consisting of one share of common stock and a Series C warrant to purchase additional common stock shares), CAMT -8.3% (announced public offering of ordinary shares, size not disclosed), JONE -6.2% (launched secondary offering of 5 mln Class A common stock by selling stockholders), FEYE -3.2% (Cisco CEO downplayed rumors that co may acquire FEYE), BIOC -2.1% (filed for $50 mln mixed securities shelf offering)